Custom generation & manufacturing of therapeutic, R&D and surrogates antibodies

In order to address the challenge of raising innovative monoclonals against haptens and membrane proteins, SYnAbs has developed a set of technologies, combining :

Innovative antigen design via proprietary assets such as SYnDNA vector, conformational SYnPEP peptides, SYnCell syngeneic cell lines and in-house adjuvant
Multi-species immunization in proprietary rat-LOU species, wild type and ATX-Gx transgenic mouse platform
Strategic immunization to break immune tolerance and trigger specific epitopes
Selection and isolation of rare B cell populations.

In combinaison with RD-Biotech expertise, from the mAbEXperts group:

Characterization: functional validation, affinity…
Sequencing and codon optimization
Antibody engineering: single-chain, humanized, bispecific, CAR
Recombinant manufacturing up to several grams level

Our technologies ensure the generation of high specificity and greater affinity antibodies, benefiting from natural in-vivo maturation and targeting antigens that are difficult to express in native and functionally active conformation.

The unique expertise of SYnAbs team has allow us to generate unique monoclonal antibodies on the marketplace, bringing added value in the fields of cancer immunotherapy, endocrinology and auto-immune diseases. You`ll find here a few examples.

SYnabs - Model MARK-1 -Anti-rat Monoclonal Antibodies